1. Home
  2. BCDA vs SPGC Comparison

BCDA vs SPGC Comparison

Compare BCDA & SPGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • SPGC
  • Stock Information
  • Founded
  • BCDA N/A
  • SPGC 2018
  • Country
  • BCDA United States
  • SPGC United States
  • Employees
  • BCDA N/A
  • SPGC N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • SPGC
  • Sector
  • BCDA Health Care
  • SPGC
  • Exchange
  • BCDA Nasdaq
  • SPGC Nasdaq
  • Market Cap
  • BCDA 9.4M
  • SPGC 7.4M
  • IPO Year
  • BCDA N/A
  • SPGC 2023
  • Fundamental
  • Price
  • BCDA $3.18
  • SPGC $0.51
  • Analyst Decision
  • BCDA Strong Buy
  • SPGC
  • Analyst Count
  • BCDA 1
  • SPGC 0
  • Target Price
  • BCDA $60.00
  • SPGC N/A
  • AVG Volume (30 Days)
  • BCDA 57.4K
  • SPGC 79.8K
  • Earning Date
  • BCDA 08-07-2024
  • SPGC 08-15-2024
  • Dividend Yield
  • BCDA N/A
  • SPGC N/A
  • EPS Growth
  • BCDA N/A
  • SPGC N/A
  • EPS
  • BCDA N/A
  • SPGC N/A
  • Revenue
  • BCDA $468,000.00
  • SPGC $609,000.00
  • Revenue This Year
  • BCDA N/A
  • SPGC $732.95
  • Revenue Next Year
  • BCDA $436.41
  • SPGC $142.00
  • P/E Ratio
  • BCDA N/A
  • SPGC N/A
  • Revenue Growth
  • BCDA N/A
  • SPGC 183.26
  • 52 Week Low
  • BCDA $2.62
  • SPGC $0.36
  • 52 Week High
  • BCDA $38.10
  • SPGC $30.00
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 51.09
  • SPGC 51.60
  • Support Level
  • BCDA N/A
  • SPGC N/A
  • Resistance Level
  • BCDA $3.30
  • SPGC $0.53
  • Average True Range (ATR)
  • BCDA 0.26
  • SPGC 0.05
  • MACD
  • BCDA 0.01
  • SPGC -0.02
  • Stochastic Oscillator
  • BCDA 97.98
  • SPGC 86.68

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About SPGC Sacks Parente Golf Inc.

Sacks Parente Golf Inc is a technology-forward golf company, with a growing portfolio of golf products, including putting instruments, golf shafts, golf grips, and other golf-related products. It designs, manufactures, and sells technology-forward, golf equipment, which is comprised of putting instruments, golf shafts, golf grips, and related product groups. It designs its golf products to fit golfers of all skill levels, amateur and professional. Its business segments currently include, golf putting instruments, golf shafts, and golf related products.

Share on Social Networks: